To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
OE Original Cover

Platelet-Rich Plasma for Knee Osteoarthritis

Share
Cite This
+ Favorites
Share
Cite This
+ Favorites
December 19, 2023

Platelet-Rich Plasma for Knee Osteoarthritis

Vol: 6| Issue: 7| Number:1| ISSN#: 2563-559X

Authored By: Ellen Scholl, Alex Thabane, Steve Phillips, Sushmitha Pallapothu and Mohit Bhandari on Behalf of OrthoEvidence

Banner Image
Osteoarthritis is a leading cause of pain and disability worldwide, an estimated prevalence of 529 million people in 2020 [1]. With aging populations across the globe, this number is expected to rise over the next two decades: cases of knee osteoarthritis (KOA) are projected to increase 74.9% by 2050 [1]. Many different management strategies exist for KOA, such as exercise, physical therapy or pain medication. But, as a progressive disease with no cure, the end result is often patients requiring costly and invasive surgical treatment, such as total joint replacement [2]. This leaves health care systems around the world with an enormous economic burden that is only expected to grow [1]. Understandably, there is considerable interest in nonoperative treatment, especially those with the potential to slow or reverse the progression of the disease [2]. Enter, intraarticular injections like platelet-rich plasma (PRP). Late 20th century pre-clinical research on PRP was encouraging [3]. Its mechanisms for promoting tissue regeneration made it a promising treatment for a variety of conditions, including KOA, where the high concentration of growth factors and cytokines could potentially counteract important aspects of KOA pathophysiology...
OE OriginalPreview Image

SHARE THIS OE ORIGINAL

Loading...

Join the Conversation

Please Login or Join to leave comments.